STEPHEN L. CARTT

Corporate Board Profile

Tech Score: 0/100

Lineage Cell Therapeutics, Inc.

Filing Date	Source Excerpt
2014-10-14	Stephen L. Cartt, 51, has served on a transitional basis as Chief Operating Officer of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc since August 2014... The following table shows the annual cash fees paid to our Chairman of the Board, our directors other than the Chairman... Director other than Chairman $30,000.
2015-06-11	Stephen L. Cartt, 52, joined our Board of Directors during November 2014. Mr. Cartt served as Chief Operating Officer of Questcor Pharmaceuticals, Inc., from February 2012 until August 2014, when the company was acquired by Mallinckrodt plc. Mr. Cartt brings to our Board his many years of experience in the pharmaceutical industry, including experience in senior management of a rapidly growing biopharmaceutical company. The members of the Compensation Committee are Deborah Andrews (Chairwoman), David Schlachet, and Stephen L. Cartt. Stephen L. Cartt received $12,125 in fees and $25,571 in option awards for a total of $37,696.

Filing Date

Source Excerpt

2014-10-14

Stephen L. Cartt, 51, has served on a transitional basis as Chief Operating Officer of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc since August 2014... The following table shows the annual cash fees paid to our Chairman of the Board, our directors other than the Chairman... Director other than Chairman $30,000.

2015-06-11

Stephen L. Cartt, 52, joined our Board of Directors during November 2014. Mr. Cartt served as Chief Operating Officer of Questcor Pharmaceuticals, Inc., from February 2012 until August 2014, when the company was acquired by Mallinckrodt plc. Mr. Cartt brings to our Board his many years of experience in the pharmaceutical industry, including experience in senior management of a rapidly growing biopharmaceutical company. The members of the Compensation Committee are Deborah Andrews (Chairwoman), David Schlachet, and Stephen L. Cartt. Stephen L. Cartt received $12,125 in fees and $25,571 in option awards for a total of $37,696.

Data sourced from SEC filings. Last updated: 2026-02-03